⚠ Nothing Left to Buy at a Sane PriceModerate threat

Marvell's current shape was bought: Cavium, Aquantia, Avera, Inphi, Innovium. The company has been unusually good at identifying assets whose value the market had not yet priced, and integrating them. The strategy has one requirement — reasonably priced targets — and that requirement is no longer being met.

Anything credibly positioned in AI infrastructure now trades at a valuation that assumes the boom continues, and the bidders include companies with vastly deeper pockets. A growth strategy built on buying is a strategy that stops working exactly when its category becomes fashionable, which is now.

The uncomfortable corollary is that Marvell's own currency has appreciated too — roughly $227 billion of market value¹ — and an expensive stock feels cheap to spend. That combination, a rich acquirer in a rich market with a track record that invites the next deal, is where good acquirers have historically made their one bad one.

What would confirm the risk is a large deal at a full multiple justified by strategic fit rather than returns. Watch the price paid relative to the target's revenue, and watch whether management can articulate the return rather than the rationale. Discipline is the asset here, and it is not visible until it fails.